{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.6","value":"231.68"},{"groupId":"OG001","spread":"40.0","value":"628.01"},{"groupId":"OG002","spread":"34.2","value":"703.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Week1 AM dose;n=4,10,5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"62.0","value":"166.62"},{"groupId":"OG001","spread":"27.6","value":"445.17"},{"groupId":"OG002","spread":"29.3","value":"425.76"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Week1 PM dose;n=4,9,5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.1","value":"284.71"},{"groupId":"OG001","spread":"66.4","value":"604.38"},{"groupId":"OG002","spread":"18.1","value":"419.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Week3 AM dose;n=3,7,3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.0","value":"256.08"},{"groupId":"OG001","spread":"41.3","value":"263.72"},{"groupId":"OG002","spread":"34.8","value":"229.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"Week3 PM dose;n=3,6,3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Blood samples were collected at indicated time points post ante-meridiem (AM) and post-meridiem (PM) dose for pharmacokinetic analysis of GSK525762.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK Parameter Population. Only those participants with data available at the specified time points were analyzed (indicated by n=X in category titles)","reportingStatus":"POSTED","timeFrame":"pre-dose,0.25,0.5,1,2,4,8,12 hours post-AM dose at Week1Day1 and Week3 Day 4; Week1 Day5(0.5, 3 hours post-AM dose); pre-dose, 0.25,0.5,1,2,4,8,12, 36 hours post-PM dose at Week1Day1 and Week3 Day4","title":"Maximum Observed Concentration of GSK525762-Part 1 BID","type":"SECONDARY","unitOfMeasure":"Nanogram per milliter"}